Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome.

M ConnellAndrea S ShinT James-StevensonH XuT F ImperialeJ Herron

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2018)

In this systematic review and meta-analysis, there was a trend toward improvement in overall response with VSL#3, but no clear evidence effectiveness for IBS. However, the number and sample sizes of the trials are small and the overall quality of evidence for 3 of the 5 outcomes was low. Larger trials evaluating validated endpoints in well-defined IBS patients are warranted.

Keyphrases

irritable bowel syndrome
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
type diabetes
metabolic syndrome
patient reported outcomes
adipose tissue
bacillus subtilis